Still’s disease in a patient with common variable immunodeficiency: NFKB1 defect
Authors:
- Anna A. RoppeltARAnna A. Roppelt
- Еkaterina A. NikitaevaЕNЕkaterina A. Nikitaeva
- Gerelma V. AndrenovaGAGerelma V. Andrenova
- Ulyana A. MarkinaUMUlyana A. Markina
- Tatyana S. KruglovaTKTatyana S. Kruglova
- Elena A. BaryakhEBElena A. Baryakh
- Zinaida Yu. MutovinaZMZinaida Yu. Mutovina
- Rinat R. MudarisovRMRinat R. Mudarisov
- Alexander V. KaraulovAKAlexander V. Karaulov
- Maryana A. LysenkoMLMaryana A. Lysenko
- Darya S. FominaDFDarya S. Fomina
- 27 August 2025
- journal article
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 22 (4) , 422-431
Abstract
Сommon variable immunodeficiency is the most prevalent form of inborn errors of immunity, however, genetic cause may be identified in less than a third of the cases. Pathogenic variants in the subunit 1 of nuclear factor κB are thought to be one of the most frequent monogenic causes of common variable immunodeficiency. Besides the humoral immunodeficiency, NFKB1 defect is characterized by a wide range of autoimmune, autoinflammatory and hematological features. To date, there are no standardized guidelines for immunosuppressive or anti-inflammatory therapy in patients with NFKB1 deficiency. We report on a 62 year old woman with common variable immunodeficiency due to heterozygous mutation in the NFKB1 gene, complicated by a systemic form of Still’s disease. Since initiation of the anti-cytokine therapy with the interleukin 6 antagonist olokizumab, resolution of constitutional symptoms has been achieved. Over the 1.5-years follow-up there has been an improvement on lymphadenopathy and joint syndrome according to computed tomography scan and ultrasound. Variety of manifestations of immune disregulation in complex of symptoms of NFKB1 defect forces a neccessity of awareness of the specialists and requires a multidisciplinary approach to selection of an optimal tactic to patient treatment.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trialsRheumatology, 2024
- NF-κB in biology and targeted therapy: new insights and translational implicationsSignal Transduction and Targeted Therapy, 2024
- Long-term follow up of families with pathogenic NFKB1 variants reveals incomplete penetrance and frequent inflammatory sequelaeClinical Immunology, 2022
- CorrigendaJournal of Allergy and Clinical Immunology, 2021
- CorrigendumJournal of Allergy and Clinical Immunology, 2021
- There is no gene for CVID — novel monogenetic causes for primary antibody deficiencyCurrent Opinion in Immunology, 2021
- Nuclear factor κB mutations in human subjects: The devil is in the detailsJournal of Allergy and Clinical Immunology, 2018
- Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in EuropeansJournal of Allergy and Clinical Immunology, 2018
- Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable ImmunodeficiencyThe American Journal of Human Genetics, 2015
- Germline Mutations in NFKB2 Implicate the Noncanonical NF-κB Pathway in the Pathogenesis of Common Variable ImmunodeficiencyThe American Journal of Human Genetics, 2013